Executive Order: Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
Summary
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.Directs CDC and ACIP to update the childhood vaccine schedule to align with peer countries that recommend fewer vaccines.
- 2.Requires all federal actions, regulations, and funding to align with the updated ACIP-recommended schedule.
- 3.Maintains coverage without cost sharing for all vaccines on the updated schedule under private insurance, Medicaid, CHIP, and Vaccines for Children Program.
- 4.Emphasizes protecting religious liberty and parental authority in vaccine policies.
- 5.Orders HHS to inform state officials of the scientific assessment and updated schedule to influence state vaccination laws.
Market Implications
The order introduces uncertainty for vaccine manufacturers by signaling a potential reduction in the number of recommended childhood vaccines, which could lower demand and revenue for companies with large pediatric vaccine portfolios.
Full Analysis
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.